COMPANY PROFILE

Valitor

Explore full profile

A biotechnology company founded to develop advanced, protein-based drugs

Berkeley, United StatesFounded 2010Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Valitor

Valitor, Inc. is a biotechnology company focused on developing advanced therapeutic solutions for life-threatening and function-threatening diseases. Originating from UC Berkeley, Valitor's core technology platform allows the creation of multivalent protein (MVP) conjugates by attaching multiple bioactive molecules, such as camelid antibodies and cytokines, to single-chain, soluble biopolymers. This proprietary technology results in BioBetter products with enhanced pharmacological properties, offering superior efficacy, durability, and safety compared to existing treatments. Valitor primarily serves patients with mobility-threatening joint diseases, life-threatening cancers, and vision-threatening ophthalmic diseases. The company operates in the biopharmaceutical market, targeting healthcare providers and institutions. Valitor's business model revolves around the research, development, and commercialization of its proprietary therapeutic products, generating revenue through product sales and potential licensing agreements.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Berkeley, United States
Employees: 21
Open positions: None listed
Dealroom signal: 73.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Oct 2022	$28M	$112M	Pandect Bioventures · ExSight Ventures · Berkeley Catalyst Fund · First Spark Ventures	↗
EARLY VC✓Equity / VC	Jan 2022	$8.4M	$34M	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Valitor website traffic

Latest recorded traffic for Valitor is 500 monthly website visits, up 8.7% over the last three months. Valitor's team grew 10.5% over the past year.

Latest monthly visits500 3-month web change+8.7% 1-year team growth+10.5%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTCyclone TherapeuticsA preclinical-stage drug discovery company that focuses on improving protein quality control by modulating translation	San Diego, United States	Operational	1	$800K	$3.2M
BTBeijing Likang Life TechnologyChina's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical tri	China	Operational
DBDiffuse BioWe're building push-button software for drug design, driven by breakthroughs in generative AI	San Francisco, United States	Operational
STSOLID TherapeuticsSOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen	Copenhagen, Denmark	Operational
OKON KOBIGSThe next generation of innovations and drug development companies, Oncovigs	Yongin-si, South Korea	Operational
EPEpiBiologicsExpanding Protein Degradation to Membrane and Extracellular Targets	San Mateo, United States	Operational
VIVicinitasAdvancing a one-of-a-kind protein stabilization platform to develop novel therapeutics for cancer and genetic disorders	South San Francisco, United States	Operational
MAMatchpointDesigning a new era of precision covalent medicines informed by breakthroughs in ultradeep chemoproteomics and machine learning	Boston, United States	Operational